• Go HOME
  • About us
  • Notice: Undefined offset: 2 in /home/host/nexelcatalog20/www/html/_skin/layout/inc_navigation_middle.php on line 60 Notice: Undefined offset: 2 in /home/host/nexelcatalog20/www/html/_skin/layout/inc_navigation_middle.php on line 86 Notice: Undefined offset: 3 in /home/host/nexelcatalog20/www/html/_skin/layout/inc_navigation_middle.php on line 86

About usGreeting of CEO

Make a Better Place

NEXEL is committed to become a world-class biotech company. We aim to develop innovative new therapies to help patients and provide to tools for researchers to boost their projects. Thus, we will create value for our investors, our fellow researchers, and our world and fulfill our mission to “Make a Better Place”

NEXEL is a world leader in iPSC (induced Pluripotent Stem Cell) technology as the first Korean company to license iPS technology and setting a new paradigm in the in vitro toxicity field through successful commercialization of iPS-derived cells which mimic actual human functionality. Furthermore, we are investing our expertise into the discovery and development of new drug candidates based on proteins and peptides derived from stem cell technology.

Our team consists of talented individuals who share a passion for innovation and high scientific standards. They are assisted by our valuable collaborators within the academic and clinical communities. This is the engine moving NEXEL closer and closer every day to achieve its mission.

We ask for your continuous support, as NEXEL evolves into the company it aspires to be.

Thank you.CEOChoong-seong Han

About usHistory

2021’s

April
Completed Series B bridge funding
March
MoU signed with KangWon National University School of Medicine for collaborative research in the field of pulmonary fibrosis treatment
February
Registered "US Patent" for New Drug Candidate for Liver Fibrosis

2020’s

May
MoU signed with Chonnam National University Hospital
April
Strategic partnership with Nanion Technologies to open reference lab in Korea for CardioExcyte96 FLEXcyte96

2019’s

August
Completed Series B funding
August
Distribution agreement signed with KAC in the Japan for hiPSC-derived cell products
May
Novartis drug development team(VP level) visits NEXEL HQ
March
Distribution agreement signed with Cambridge Bioscience in the U.K. and Ireland for hiPSC-derived cell products

2018’s

June
Innobiz Certification
May
Commercial license (non-exclusive) for hiPSC-derived cell products obtained from iPS Academia Japan
March
ISO9001 certification

2017’s

December
Distribution agreement with BOYA Medical for the distribution of iPSC-derived cell products

2016’s

March
Corporate affiliated research institute certified
February
Venture company certified

2015’s

May
Name changed to NEXEL Co., Ltd.

2012’s

September
Founding of NEXCELL Bio

About usResources

Patent/License

# Name Registration
[Patent ID]
Note
23 Compositions and Method for Treating or Preventing Fibrosis PCT/IB2019/001136 fibrosis treatment
22 Methods for producing in vitro wilson's disease model using human pluripotent stem cell and in vitro wilson's disease model produced by thereof 10-2159877/ KR
PCT/KR2019/001278
Wilson's dsease model
21 Composition for predicting prognosis of senere alcoholic hepatitis and use thereof 10-2171799/ KR
PCT/KR2019/002392
Biomarker for alcholic hepatitis
20 Method for differentiation of hepatocyte 10-2038503/ KR Hepatic maturation
19 Method for enhancing metabolizing activity of hepatocytes 10-2018783/ KR Hepatic differentiation
18 Composition for Idiopathic Pulmonary Fibrosis treatment or prevention containing recombinant protein for Idiopathic Pulmonary Fibrosis treatment or prevention 10-2161892/ KR
PCT/KR2018/012801
Use of NP-011 for IPF disease
17 Composition for Alzheimer"s disease treatment or prevention containing recombinant protein for Alzheimer"s disease treatment or prevention 10-2129179/ KR
PCT/KR2018/012800
Use of NP-011 for Alzheimer"s disease
16 Composition for myocardial infarction treatment or prevention containing recombinant protein for myocardial infarction treatment or prevention 10-2129178/ KR
PCT/KR2018/012780
Use of NP-011 for MI disease
15 Methods for differentiation of glutamatergic neuron from human plufipotent stem cell using insulin-like growth factor 1 receptor inhibitor 10-2183230/ KR
PCT/KR2019/007266
Neural differentiation
14 Simple method for differentiating human pluripotent stem cells into highly proliferative vascular endothelial cells for hemophilia A treatment 10-2161910/ KR Vascular endothlial cells differentiation
13 Methods for preparing in vitro cultured hepatocytes using er stress reliever and in vitro cultured hepatocytes prepared by thereof
(Partition application: primary Hepatocytes)
10-2145134/ KR Hepatocyte cultivation
12 Methods for preparing in vitro cultured hepatocytes using er stress reliever and in vitro cultured hepatocytes prepared by thereof(Partition application: liver cancer cells) 10-2159886/ KR Hepatocyte cultivation
11 Methods for preparing in vitro cultured hepatocytes using er stress reliever and in vitro cultured hepatocytes prepared by thereof 10-2060256/ KR
PCT/KR2018/012609
Hepatocyte cultivation
10 Method for generating human pluripotent stem cells derived functional cardiomyocytes by cell differentiation with maturation and hauman pluripotent stem cell derived functional cardiomyocytes generated by thereof 10-1994035/ KR
PCT/KR2018/004195
Differentiation and production of mature cardiomyocytes
9 Recombinant protein for treatment or prevention and composition for treatment or prevention containing thereof(Partition application: Excluding signal peptide) 2019-160324/ JP NP-011 and the use of NP-001 for curing liver disease
8 Recombinant protein for treatment or prevention and composition for treatment or prevention containing thereof 10-1947902/KR, PCT/KR2017/005150, 17870624.8/EU, 2018-524465/JP, 15/994.323/US, 201780004259.5/CN NP-011 and the use of NP-011 for curing liver disease
7 Method for differentiation of hepatocyte derived from human stem cells and Hepatocyte 10-1918817/ KR
201710066109.9/ CN
Massive production of hepatocytes
6 Use fo liver regeneration and improvement of liver diseases of using milk for globule-EGF factor 8 PCT/KR2016/007611
201680002518.6(CN)
Use of MFG-E8 for curing chronic liver diease
5 Use of liver regeneration and improvement of liver diseases of using milk fat globule-EGF factor 8 10-1486114/ KR
201770724722.1(CN)
use of MFG-E8 for curing acute liver disease
4 Compositions for treatment of liver disease comprising conditioned medium obtained by culturing hepatocytes differentiated from human embryonic stem cells 10-1263760/ KR Therapeutic use of human stem cell secretome
3 Metuods for inducing differentiation from human embrionic stem cells to dopaminergic neurons by using vascular endothelial growth factor 10-0856706/KR Neural differentiation
2 Method for differentiation of pancreatic progenitor cells fron human embryonic stem cells 10-0885854/KR Pancreatic differentiation
1 Method of Induction differentiation of Stem Cells 10-0861632/KR Hepatic differentiation

Research Paper

Year Title Journal
2021 Generation of uniform liver spheroids from human pluripotent stem cells for imaging-based drug toxicity analysis DOI:10.1016/j.biomaterials.2020.120529 Biomaterials
2021 Human pluripotent stem-cell-derived alveolarorganoids for modeling pulmonary fibrosis anddrug testing DOI:/10.1038/s41420-021-00439-7 Cell Death Discovery
2021 Dose Optimization of Vancomycin Using a Mechanism-based ExposureeResponse Model inPediatric Infectious Disease Patients DOI:10.1016/j.clinthera.2020.10.016 Clinical Therapeutics
2020 Milk Fat Globule-EGF Factor 8 Contributes to Progression of Hepatocellular Carcinoma DOI:10.3390/cancers12020403 MDPI Cancers
2020 Human Embryonic Stem Cell-Derived Wilson’s Disease Model for Screening Drug Efficacy DOI: 10.3390/cells9040872 MDPI Cells
2020 Characterization of Endoplasmic Reticulum (ER) in Human Pluripotent Stem Cells Revealed Increased Susceptibility to Cell Death upon ER Stress DOI: 10.3390/cells9051078 MDPI Cells
2020 ER stress reliever enhances functionalities of in vitro cultured hepatocytes DOI: 10.1016/j.scr.2020.101732 Stem Cell Research
2020 Modulating cardiomyocyte and fibroblast interaction using layer-by-layer deposition facilitates synchronisation of cardiac macro tissues DOI: 10.1039/c9sm01531k Soft Matter
2020 Alterations of Ca2+ signaling and Ca2+ relese sites in cultured ventricular myocytes with intact internal Ca2+ storage DOI:10.1016/j.bbrc.2020.04.059 BBRC
2020 Milk Fat Globule-Epidermal Growth Factor VIII Ameliorates Brain Injury in the Subacute Phase of Cerebral Ischemia in an Animal Model DOI: 10.3340/jkns.2019.0188 KNS
2019 Automated Dynamic Clamp for Simulation of IK1 in Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes in Real Time Using Patchliner Dynamite8 DOI: 10.1002/cpph.70 Current Protocols in Pharmacology
2019 Synthetic probes for in vitro purification and in vivo tracking of hepatocytes derived from human pluripotent stem cells DOI:10.1016/j.biomaterials.2019.119431 Biomaterials
2019 Collagen Type I Containing Hybrid Hydrogel Enhances Cardiomyocyte Maturation in a 3D Cardiac Model DOI:10.3390/polym11040687 MDPI polymers
2019 Distinct shear-induced Ca2+ signaling in left and right atrial myocytes: Role of P2 receptor context DOI:10.1016/j.yjmcc.2020.04.018 JMCC
2018 Prediction of hepatotoxicity for drugs using human pluripotent stem cell-derived hepatocytes DOI 10.1007/s10565-017-9392-y Cell Biol Toxicol
2018 Rho-associated kinase inhibitor enhances the culture condition of isolated mouse salivary gland cells in vitro DOI: 10.1016/j.tice.2018.07.002 Tissue and Cell
2018 Human induced pluripotent stemcell linewith cytochrome P450 enzyme polymorphism (CYP2C19*2/CYP3A5*3C) generated from lymphoblastoid cells DOI:10.1016/j.scr.2017.12.014 Stem Cell Research
2017 Milk Fat Globule‒EGF Factor8, secreted by Mesenchymal stem cells protects Against Liver Fibrosis in Mice DOI: 10.1053/j.gastro.2016.12.003 Gastroenterology
2017 Using a neonatal rat system as a bioincubator to generate adult-like mature cardiomyocytes from human and mouse pluripotent stem cells DOI: 10.1038/nprot.2017.089 Nature protocol
2017 Current Understanding of Stem Cell and Secretome Therapies in Liver Diseases DOI: 10.1007/s13770-017-0093-7 Tissue Eng Regen Med
2017 Neonatal Transplantation Confers Maturation of PSC-Derived Cardiomyocytes Conducive to Modeling Cardiomyopathy DOI: 10.1016/j.celrep.2016.12.040 Cell Reports
2017 Prediction of hepatotoxicity for drugs using human pluripotent stem cell-derived hepatocytes DOI: 10.1007/s10565-017-9392-y Cell Biology and Toxicology
2016 Enhancing a Wnt-Telomere Feedback Loop Restores Intestinal Stem Cell Function in a Human Organotypic Model of Dyskeratosis Congenita DOI:10.1016/j.stem.2016.05.024 Cell Stem Cell
2016 Functional Connection with Cardiac Tissues Confers Maturation Phenotypes in hPSC-Derived PHOX2B::GFP Expressing Sympathetic Neurons DOI: 10.1016/j.stem.2016.05.002 Cell stem cell
2016 Nanotopography Promotes Pancreatic Differentiation of Human Embryonic Stem Cells and Induced Pluripotent Stem Cells DOI: 10.1021/acsnano.5b06985. ACS nano
2016 Comparison of adult stem cells derived from multiple stem cell niches DOI: 10.1007/s10529-016-2050-2. Biotechnology Letters
2015 Functional Correction of Large Factor VIII Gene Chromosomal Inversions in Hemophilia A Patient‒Derived iPSCs Using CRISPR‒Cas9 DOI: 10.1016/j.stem.2015.07.001. Cell Stem Cell
2015 The Msi Family of RNA‒Binding Proteins Function Redundantly as Intestinal Oncoproteins DOI: 10.1016/j.celrep.2015.11.022. Cell Reports
2015 Enhanced Metabolizing Activity of Human ES Cell‒Derived Hepatocytes Using a 3D Culture System with Repeated Exposures to Xenobiotics DOI: 10.1093/toxsci/kfv121 Toxicological Sciences
2014 Phosphodiesterase 9A Controls Nitric-oxide Independent cGMP and Hypertrophic Heart Disease DOI: 10.1038/nature14332 Nature
2014 Mitochondrial Induced and Self‒Monitored Intrinsic Apoptosis by Antitumor Theranostic Prodrug: In Vivo Imaging and Precise Cancer Treatment DOI: 10.1021/ja510421q JACS
2014 Regenerative medicine for the heart: perspectives on stem-cell therapy DOI: 10.1089/ars.2014.6063. ARS
2013 Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells DOI: 10.1016/j.ccr.2013.04.008 Cancer Cell
2012 Direct and Indirect Contribution of Human Embryonic Stem Cell‒Derived Hepatocyte‒Like cells to Liver Repair in Mice DOI: 10.1053/j.gastro.2011.11.030 Gastroenterology